Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Formycon AG
FYBCurrent price
46.35 EUR
-0.15 EUR (-0.32%)
Last closed
46.8 EUR
Company
www.formycon.com
ISIN
DE000A1EWVY8
Sector
Healthcare
Industry
Biotechnology
Exchange
XETRA Stock Exchange
Capitalization
854 256 400 EUR
Yield for 12 month
-24.26 %
1Y
3Y
5Y
10Y
15Y
FYB
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranpoto, Uptera, and Ravegza names. The company's pipeline includes FYB202, a biosimilar candidate for Stelara used in the treatment of Psoriasis, Crohn's disease, and ulcerative colitis which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea that treats ophthalmology related diseases, including neovascular age-related macular degeneration that has completed Phase III clinical trials. It is also developing FYB206, a biosimilar candidate for Keytruda, for the treatment of immuno-oncology diseases; and FYB207, a SARS-CoV-2 blocker, an antiviral drug for the treatment of COVID-19. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany. Address: Fraunhoferstrasse 15, Planegg, Germany, 82152
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
85.25 EURP/E ratio
11.8734Dividend Yield
–Current Year
+78 524 661 EUR
Last Year
+42 950 249 EUR
Current Quarter
+27 179 825 EUR
Last Quarter
+34 268 633 EUR
Current Year
+23 553 558 EUR
Last Year
+12 200 753 EUR
Current Quarter
+1 928 350 EUR
Last Quarter
+5 729 462 EUR
Key Figures FYB
1 year
3 years
5 years
10 years
EBITDA
-24 706 727 EUR
Operating Margin TTM
PE Ratio
11.8734
Return On Assets TTM
-1.69 %
PEG Ratio
–
Return On Equity TTM
12.73 %
Wall Street Target Price
85.25 EUR
Revenue TTM
61 448 458 EUR
Book Value
32.99 EUR
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-38.6 %
Dividend Yield
–
Gross Profit TTM
1 016 729 EUR
Earnings per share
4.07 EUR
Diluted Eps TTM
4.07 EUR
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
-98.2 %
Profit Margin
105.09 %
Dividend Analytics FYB
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History FYB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
385:383
Payout Ratio
–
Last Split Date
08.11.2013
Dividend Date
–
Stock Valuation FYB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
11.8734
Forward PE
92.5926
Enterprise Value Revenue
13.2527
Price Sales TTM
13.902
Enterprise Value EBITDA
12.4535
Price Book MRQ
1.4498
Financials FYB
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators FYB
For 52 weeks
38.05 EUR
68.52 EUR
50 Day MA
51.15 EUR
Shares Short Prior Month
–
200 Day MA
49.42 EUR
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart